Person:
ÖZARDA, YEŞİM

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

ÖZARDA

First Name

YEŞİM

Name

Filters

2019 - 201912020 - 20211
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Stability of hematological analytes during 48 hours storage at three temperatures using cell-dyn hematology analyzer
    (Soc Medical Biochemists Serbia, 2021-01-01) Özmen, Sevda Ünalli; Özarda, Yeşim; ÖZARDA, YEŞİM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı; AAL-8873-2021
    Background: The complete blood count (CBC) with differential leukocyte count (DLC) is one of the most common tests requested by physicians. The results of this test are affected by storage temperature and time of incubation. This study was designed to evaluate the stability of hematologic parameters in blood specimens stored for 48 h at three temperatures.Methods: K-2-EDTA - blood was collected from 22 healthy adults. The CBC was performed using a hematology analyser immediately; 0 time point and at 4, 8, 12, 16, 20, 24, and 48 h after storage at 4 degrees C, 10 degrees C or 23 degrees C. Changes in values of CBC parameters from the 0 time point were determined and reported as % of the initial value.Results: Red blood cells, platelet, hemoglobin, and mean corpuscular hemoglobin were found stable during 48 h storage at 4 degrees C, 10 degrees C or 23 degrees C. Hematocrite and mean corpuscular volume increased, while white blood cells decreased at 48 h when stored at 23 degrees C. Lymphocytes, neutrophils, eosinophils, and basophils showed significant differences after 12 h of storage at 23 degrees C.Conclusions: Red blood cells, platelet, hemoglobin, and mean corpuscular hemoglobin are the only suitable parameters without refrigeration during 24 h storage. When CBC and DLC are performed, 4 degrees C can be recommended as the most suitable storage temperature for 12 h storage.
  • No Thumbnail Available
    Publication
    Relationship with excessive daytime sleepiness and serum substance P levels in OSAS patients and the effect of PAP treatment
    (Springer Japan, 2019-07-01) Güçlu, Özge Aydın; Ursavaş, Ahmet; Kasapoğlu, Fikret; Özarda, Yeşim; Bozyiğit, Cengiz; Ocakoğlu, Gökhan; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; KASAPOĞLU, FİKRET; ÖZARDA, YEŞİM; BOZYİĞİT, CENGİZ; OCAKOĞLU, GÖKHAN; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kulak Burun Boğaz Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0003-1005-3205; 0000-0003-2215-6973; 0000-0002-1114-6051; 0000-0002-9027-1132; AAI-3877-2021; AAI-3169-2021; AAH-5180-2021; AAL-8873-2021; HLG-6346-2023; AAG-8744-2021; AAG-9930-2019; AAE-1623-2022
    Obstructive sleep apnea syndrome (OSAS) is a commonly seen disorder characterized by repeated episodes of upper airway obstruction during sleep leading to intermittent hypoxemia or arousal. We aim to evaluate the effects of positive airway pressure (PAP) treatment on daytime sleepiness and serum Substance P (SP) levels in OSAS patients. Seventy-one consecutive patients with newly diagnosed OSAS and 19 non-apneic control subjects were enrolled to the study. PAP treatment indicated subjects were re-evaluated after 3 months of treatment. Morning SP levels of OSAS patients and Epworth sleepiness scale (ESS) were assessed at the beginning and then after 3 months of PAP treatment. Of the patients 71 (78.9%) were male and 19 (21.1%) were female, with a median age of 45 [20-62]. The levels of SP in the OSAS group were significantly lower than the snorer group and a significant correlation was not found between serum levels of SP and ESS. SP levels were negatively correlated with AHI. The baseline SP median was 336.1pg/mL [121.6-536.1], while the 3rd month SP median was 213.1pg/mL [103.5-727.6]. Serum SP values were found to have significantly decreased at 3months (p<0.0001). Statistically significant correlation was not found between percentage of ESS change and the percentage of SP change. It can be assumed that the SP level is reduced as part of the compensation mechanism in OSAS cases and supporting this mechanism, the PAP therapy further reduces the SP value by relieving the cases from apnea and the intermittent hypoxia burden.